Vir Biotechnology (VIR) director granted RSUs and 16,000-share stock option
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vir Biotechnology, Inc. director Robert J. More reported equity awards and updated his holdings. He received 8,000 restricted stock units (RSUs) under the company’s Equity Incentive Plan, which will vest in full on May 27, 2027. He also received a stock option for 16,000 shares of common stock at an exercise price of $9.10 per share, vesting and becoming exercisable in full on May 27, 2027 and expiring on May 26, 2036. Following these awards, he directly holds 48,656 shares of common stock and 16,000 option shares. An additional 509,917 shares are held for the benefit of Alta Partners NextGen Fund I, L.P.; More may be deemed to beneficially own these through his role with its general partner but disclaims beneficial ownership except for his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
MORE ROBERT J
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 16,000 | $0.00 | -- |
| Grant/Award | Common Stock | 8,000 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 16,000 shares (Direct, null);
Common Stock — 48,656 shares (Direct, null);
Common Stock — 509,917 shares (Indirect, See footnote)
Footnotes (1)
- Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. The RSUs will vest in full on May 27, 2027. Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of RSU awards. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.
Key Figures
RSU grant: 8,000 RSUs
Option grant size: 16,000 shares
Option exercise price: $9.10 per share
+5 more
8 metrics
RSU grant
8,000 RSUs
Equity Incentive Plan grant vesting May 27, 2027
Option grant size
16,000 shares
Stock option underlying common stock
Option exercise price
$9.10 per share
Stock option strike price
RSU vesting date
May 27, 2027
RSUs vest in full on this date
Option vesting date
May 27, 2027
Option becomes fully exercisable on this date
Option expiration
May 26, 2036
Stock option expiration date
Direct common shares
48,656 shares
Direct holdings after transactions
Indirect fund-related shares
509,917 shares
Held for Alta Partners NextGen Fund I, L.P.
Key Terms
restricted stock units (RSUs), Equity Incentive Plan, stock option, vest, +2 more
6 terms
restricted stock units (RSUs) financial
"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Equity Incentive Plan financial
"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
stock option financial
"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"The RSUs will vest in full on May 27, 2027."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
pecuniary interest financial
"However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein,"
beneficial ownership financial
"As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What equity awards did Vir Biotechnology (VIR) director Robert J. More receive?
Robert J. More received 8,000 restricted stock units and a stock option for 16,000 shares. Both awards were granted under Vir Biotechnology’s Equity Incentive Plan as compensation and are scheduled to vest in full on May 27, 2027, subject to continued service.
When do Robert J. More’s new Vir Biotechnology (VIR) RSUs and options vest?
Both the 8,000 RSUs and the 16,000-share stock option vest and become exercisable in full on May 27, 2027. This single cliff-vesting date means no partial vesting occurs before then, concentrating the value realization on that future date.
What is the exercise price and term of Robert J. More’s Vir (VIR) stock option?
The stock option covers 16,000 Vir Biotechnology common shares at an exercise price of $9.10 per share. It vests in full on May 27, 2027 and expires on May 26, 2036, giving roughly nine years to exercise after vesting.
What is the relationship between Robert J. More and Alta Partners NextGen Fund I in Vir (VIR)?
Shares are held for Alta Partners NextGen Fund I, L.P., whose general partner’s managing director is Robert J. More. He may be deemed to beneficially own those Vir shares but expressly disclaims beneficial ownership except for his pecuniary interest in the fund.
Were Robert J. More’s Vir Biotechnology (VIR) RSUs acquired for cash?
The 8,000 RSUs were acquired pursuant to Vir Biotechnology’s Equity Incentive Plan at a reported price of $0.00 per share. This indicates they are compensation awards, granted as part of his director role rather than purchased in an open-market transaction.